ALHC vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALHC's Advanced Deterministic Scorecard reveals significant financial health concerns, with a Piotroski F-Score of 2/9 indicating weak operational and financial stability. The absence of an Altman Z-Score and the company's high debt/equity ratio of 1.84 raise distress risk concerns, especially given negative profitability metrics and a lack of positive cash flow indicators. Despite strong revenue growth (44.4% YoY) and impressive earnings surprises in recent quarters, the company remains unprofitable with negative ROE (-0.70%) and ROA (1.00%), undermining long-term sustainability. Insider selling totaling $454.78M over six months signals strong bearish sentiment from leadership, further eroding confidence. The stock trades at a premium valuation (Price/Book: 21.89) despite poor profitability, suggesting overvaluation relative to fundamentals.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALHC vs JNJ: Head-to-Head Comparison
This page compares Alignment Healthcare, Inc. (ALHC) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.